Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate treatment.
Antibodies reacting with the cell surface of ovarian tumor cell lines were detected in the sera of untreated patients with ovarian cancer using cell surface immunofluorescence and FACS analysis. Vaccination of these patients with viral oncolysates increased the antibody production against ovarian cell surface antigens. These antibodies cross-reacted with a melanoma cell line (WM-75), and a lymphoblastoid cell line (Daudi). Immunoprecipitation and SDS-PAGE analysis of 125I-iodine labelled cell surface antigens of ovarian cells revealed a response to private and common antigens expressed on the cell surface of the tumor cells.
Ioannides
C G
CG
Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Platsoucas
C D
CD
Bowen
J M
JM
Wharton
J T
JT
Freedman
R S
RS
D000230:Adenocarcinoma / Q000276:immunology* / Q000628:therapy; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000628:therapy; D014407:Tumor Cells, Cultured; D014611:Vaccination; D014765:Viral Vaccines / Q000627:therapeutic use
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D014765:Viral Vaccines